Collins Stewart Reports on United Therapeutics

In a report released today, Collins Stewart commented on United Therapeutics UTHR. In the report, Collins Stewart was positive in its assessment of the company. Collins Stewart writes, “Our physician feedback suggests that the introduction of smaller doses has dramatically improved physician's ability to titrate to higher sustainable treprostinil doses without the GI toxicity and dropouts seen in FREEDOM-C, with the majority of physicians noting that patients can get to an effective dose in ~6 weeks. While physician demand for oral treprostinil may be dependent on the outcomes of the FREEDOM studies, physicians we spoke with believe patient demand will be high regardless of the study results, given the ease of administration vs. other available therapies.” Collins Stewart currently has a Buy rating on United Therapeutics and a price target of $80. Shares of the company closed the trading day yesterday at $65.10, down $0.61 from the opening bell.